|
|
|
28.11.25 - 16:09
|
Disclosure of major shareholder announcement (GlobeNewswire EN)
|
|
|
In accordance with section 30, cf. section 38, of the Danish Capital Markets Act, Tivoli A/S hereby announces that Augustinus Fonden has today notified Tivoli A/S that Augustinus Fondens wholly owned subsidiary Skandinavisk Holding A/S has disposed its directly owned shares in Tivoli A/S in connection with, and as a result of, the completion of the merger between Skandinavisk Holding A/S (the discontinuing company) and the Augustinus Foundation's wholly owned subsidiary Chr. Augustinus Fabrikker Aktieselskab (the continuing company)....
|
|
|
|
|
|
|
|
|
|
|
24.11.25 - 14:39
|
Novo Nordisk Plunges After Ozempic Pill Fails Alzheimer′s Trials - Shares Suffer Worst Year Ever (ZeroHedge)
|
|
|
Novo Nordisk Plunges After Ozempic Pill Fails Alzheimer's Trials - Shares Suffer Worst Year Ever
Shares of Novo Nordisk in Copenhagen plunged the most in nearly four months after top-line results from a two-year analysis of the evoke and evoke+ Phase 3 trials, a pill version of Ozempic, showed the treatment failed to slow progression in early-stage symptomatic Alzheimer's disease.
The studies, which enrolled 3,808 adults over two years, found improvements in Alzheimer's-related biomarkers but no meaningful impact on cognitive decline, as measured by the Clinical Dementia Rating (CDR-SB) score.
"While treatment with semaglutide resulted in improvement of Alzheimer's disease-related biomarkers in both trials, this did not translate into a delay of disease progression," Novo wrote in a press release.
Novo chief scientific officer Martin Holst Lange commented on the results:
"Based on the significant unmet need in Alzheimer's disease as well as a number of indicative dat...
|
|
|
24.11.25 - 13:24
|
Wdh: Abnehmmittel als Alzheimer-Hoffnung: Novo Nordisk enttäuscht mit Studie (Cash)
|
|
|
- Das Abnehmmittel Semaglutid des Pharmakonzerns Novo Nordisk hat in einer Alzheimer-Studie nicht den erwünschten Erfolg gebracht. Die zulassungsrelevante Phase-III-Studie Evoke zu Semaglutid in oraler Darreichungsform habe im Vergleich zu Placebo keine statistisch signifikante Verlangsamung des Fortschreitens der Alzheimer-Krankheit gezeigt, teilte der dänische Pharmariese am Montag mit. Der Aktienkurs von Novo Nordisk brach auf die Nachricht hin um zehn Prozent auf den tiefsten Stand seit dem Jahr 2021 ein./mis/stw...
|
|
|
24.11.25 - 13:09
|
Novo Nordisk scheitert bei Alzheimer – Aktie rauscht nach unten (Der Aktionaer)
|
|
|
Die Aktie von Novo Nordisk rauscht zum Wochenstart ordentlich nach unten. Der Grund: Die Studien zu Rybelsus, basierend auf dem Wirkstoff Semaglutid, zum Einsatz bei Alzheimer zeigten nicht den erhofften Erfolg. In den Studien Evoke und Evoke+ konnte keine Verlangsamung des Krankheitsfortschritts erzielt werden....
|
|
|
|
|
|
|
24.11.25 - 12:54
|
Novo Nordisk enttäuscht mit Alzheimer-Studie (Cash)
|
|
|
- Das Abnehmmittel Wegovy des Pharmakonzerns Novo Nordisk hat in einer Alzheimer-Studie nicht den erwünschten Erfolg gebracht. Die zulassungsrelevante Phase-III-Studie Evoke habe im Vergleich zu Placebo keine statistisch signifikante Verlangsamung des Fortschreitens der Alzheimer-Krankheit gezeigt, teilte der dänische Pharmariese am Montag mit. Der Aktienkurs von Novo Nordisk brach auf die Nachricht hin um zehn Prozent auf den tiefsten Stand seit dem Jahr 2021 ein./mis/stw...
|
|
|
24.11.25 - 12:24
|
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer′s disease progression (GlobeNewswire EN)
|
|
|
Bagsværd, Denmark, 24 November 2025 – Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease. The two trials were randomised, double-blinded, enrolled a total of 3808 adults and evaluated the efficacy and safety of oral semaglutide compared to placebo on top of standard of care. The decision to pursue an Alzheimer's disease indication with semaglutide was based on real-world evidence studies, pre-clinical models as well as post-hoc analyses from diabetes and obesity trials....
|
|
|
|
|
13.11.25 - 15:06
|
Mike Clayville Joins C3 AI Board of Directors (Business Wire)
|
|
|
REDWOOD CITY, Calif.--(BUSINESS WIRE)--C3 AI (NYSE: AI), the Enterprise AI application software company, today announced the appointment of Mike Clayville to its board of directors, effective November 9, 2025.
Mr. Clayville brings over 30 years of enterprise software and cloud infrastructure expertise. Most recently, he served as Chief Customer Officer at Stripe. Before Stripe, he led global commercial sales at Amazon Web Services, overseeing operations serving millions of customers across 170 countries.
Earlier in his career, Mr. Clayville held senior leadership roles at VMware, BEA Systems, Tivoli Systems, and IBM, leading large-scale digital transformation initiatives.
“Mike has spent his career helping companies grow and bring new technology to market,” said Stephen Ehikian, CEO, C3 AI. “He's seen firsthand how organizations adopt new technology, and how to build strong customer relationships. His perspective will be a great addition as we continue to grow C3 AI, and I look forward to working w...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
